drugset / Trial / NCT04786769

Iron Supplementation in TAVI and SAVR Patients With Iron Deficiency

NCT04786769

Phase 4 Unknown 2500 enrolled Hospital de Santa Cruz, Portugal
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The INERTIA trial is a multicenter double-blinded randomized trial of intravenous iron supplementation in patients with severe aortic stenosis and iron deficiency undergoing TAVI or SAVR. The primary endpoint is the time to HF hospital admission or cardiovascular death. Secondary endpoints will assess quality of life indicators and functional capacity at 6 months.

Timeline

Start
2022-01
Primary completion
2025-01
Completion
2025-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferric carboxymaltose Other / unclassified Intravenous